COMMUNIQUÉS West-GlobeNewswire

Innate Pharma presents early clinical data on IPH5401 and monalizumab at the ESMO 2019 congress

01/10/2019 - 07:00

IPH5401 dose-escalation study in combination with durvalumab in advanced solid tumors, STELLAR-001, shows manageable safety profile Initiation of two expansion cohorts in non-small cell lung cancer (NSCLC) with [...]

INNATE PHARMA PRÉSENTE DES RESULTATS CLINIQUES PRELIMINAIRES SUR IPH5401 ET MONALIZUMAB AU CONGRÈS DE L’ESMO 2019

01/10/2019 - 07:00

Profil de sécurité gérable de la combinaison d’IPH5401 avec durvalumab dans l’étude en escalade de dose STELLAR-001 dans des tumeurs solides avancées Deux extensions de cohorte ont démarré : dans le cancer du poumon non [...]

IBA receives down payment for Proteus®PLUS contract in Shenzhen, China

01/10/2019 - 07:00

Seven proton therapy rooms already sold by IBA this year Louvain-la-Neuve, Belgium, 1 October, 2019 - IBA ( Ion Beam Applications SA ), the world’s leading provider of proton therapy solutions for the treatment of [...]

IBA reçoit l’acompte du contrat pour un Proteus®PLUS à Shenzhen en Chine

01/10/2019 - 07:00

IBA a déjà signé des contrats pour sept salles de protonthérapie cette année Louvain-La-Neuve, Belgique, 1 er octobre 2019 - IBA (Ion Beam Applications S.A.), le premier fournisseur mondial de solutions de [...]

FibroGen Receives One of China Pharmaceutical Industry’s Highest Awards for Clinical Innovation for Roxadustat

01/10/2019 - 02:00

SAN FRANCISCO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that roxadustat received the 2019 Dushu Lake Prize 独墅湖杯in China for “On-Market Innovative Drug with Highest Clinical Value [...]

Chimerix Announces Exclusive Global License Agreement with SymBio Pharmaceuticals for Brincidofovir

01/10/2019 - 01:30

Includes All Human Indications Excluding Prevention and Treatment of Smallpox Chimerix to Receive up to $180 Million in Potential Clinical, Regulatory, and Commercial Milestones and is Eligible for Double Digit [...]

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in China

01/10/2019 - 01:00

LA JOLLA, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), [...]

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01/10/2019 - 00:03

CAMBRIDGE, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on September 30, 2019, that were [...]

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30/09/2019 - 23:00

CAMBRIDGE, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in [...]

Genfit: H1 2019 Results and R&D Pipeline Progression

30/09/2019 - 22:45

GENFIT: H1 2019 RESULTS AND R&D PIPELINE PROGRESSION Cash position of €282 million (€207 million at December 31, 2018) USD $155 million gross proceeds from the IPO on the Nasdaq Global Select market Signature of a [...]

GENFIT présente ses résultats financiers et l’avancée de son portefeuille de programmes de R&D au premier semestre 2019

30/09/2019 - 22:45

GENFIT présente ses résultats financiers et l’avancée de son portefeuille de programmes de R&D au premier semestre 2019 Trésorerie de Cloture de 282 M€ (contre 207 M€ au 31 décembre 2018) Levée de fonds d’un montant [...]

NewLink Genetics and Lumos Pharma Enter into Merger Agreement to Form Biopharmaceutical Company Focused on Developing Therapies to Treat Rare Diseases

30/09/2019 - 22:35

-- Combined company to assume the name, Lumos Pharma, Inc. and is expected to be led by Richard J. Hawkins, current CEO of Lumos Pharma -- -- Lumos asset, LUM-201, represents first oral therapeutic candidate for [...]

Geron Announces Fast Track Designation Granted to Imetelstat for Relapsed/Refractory Myelofibrosis

30/09/2019 - 22:19

MENLO PARK, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation to imetelstat for the [...]

AnaptysBio Reports Positive Topline Data from Interim Analysis of GALLOP Phase 2 Clinical Trial of ANB019 Monotherapy in Moderate-to-Severe Generalized Pustular Psoriasis

30/09/2019 - 22:15

Interim analysis conducted with first two patients to complete 16-week (Day 113) ANB019 monotherapy study Both patients achieved the primary endpoint of disease score improvement at Day 29 and Day 113 without requiring [...]

Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30/09/2019 - 22:07

HOUSTON, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today [...]

Aduro Biotech to Present at the 2019 Cantor Global Healthcare Conference

30/09/2019 - 22:05

BERKELEY, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Andrea van Elsas, chief scientific officer of Aduro, is scheduled to present at the 2019 Cantor Global [...]

Ocugen to Present at Three Upcoming Conferences

30/09/2019 - 22:05

MALVERN, Pa., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc. , (NASDAQ: OCGN) a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that [...]

Dynavax to Present at the 2019 Cantor Global Healthcare Conference

30/09/2019 - 22:05

BERKELEY, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), today announced that Ryan Spencer, Senior Vice President, Commercial, and Interim Co-President, will present at the [...]

Predictive Technology Group Reports Fiscal Year 2019 Financial Results

30/09/2019 - 22:02

Revenue increases 162% to $43.5 million with $3.5 million in positive cash flow from operations SALT LAKE CITY, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK: PRED) (the Company), a [...]